
ãããŒãã»ãããŒã³å士 æ¿åºäž»å°ã®å»çå°å¶æ¿æ²»ãè¬ãå»ãæã
å èšäºã¯ãã¡ããã/Click here to read the original article.
ççã¯ã©ã€ãªã³ã®ãããªãã®ã§ãå®ãå¿ èŠã¯ãªããã©ã€ãªã³ãèªç±ã«ããã°ãã©ã€ãªã³ã¯èªããå®ããç ç²è ã§ã¯ãªããã©ã€ãªã³ã«ãªããªããã
(ãããŒãã»ãããŒã³ïŒ - åããå»åž«ããåžæ°ããè³ã貞ããŠããã
ç§ãããã«æ¥ãã®ã¯ãéèãæ¿åºãã°ããŒããªã¹ãçµç¹ã巚倧ãªéæ¿åºçµç¹ã®æ¯é è ãã¡ã«ãã£ãŠæ¯æãããŠãããããããŠã³ã®å»çèŠå¶ãè³è³ããããã§ã¯ãªããããããããè¬ãå»ãããã§ããã
æ°åã³ãããŠã€ã«ã¹ã人é¡ç€ŸäŒã«åããŠææããŠããäžž4幎ãçµã£ãããã®ãŠã€ã«ã¹ã¯ãã¢ã¡ãªã«æ¿åºãè³éãæäŸããã¢ã¡ãªã«ã®å»çç£æ¥è€åäœãäžåœå ±ç£å ãšååããŠéçºãããã®ã§ããã
ãã®ãããããŠã³ãäžå€®éæš©çã¢ãããŒãã«ããæå®³ã«é¢ããææ°ã®ç¥èŠã«ã€ããŠèããŠã¿ãããçç·ŽããããŒã¿ç§åŠè ãã¡ã¯æè¿ãéå»è¬åçä»å ¥ãšïŒå®å šã§ã广çã§ããªãïŒæŒãã€ãã®å»çä»å ¥ã®çµã¿åããã«é¢é£ããç±³åœã®è¶ éæ»äº¡è æ°ã50äžäººãè¶ ãããšæšå®ããŠããã
ç±³åœæ¿åºãšCIAã®åœ±é¿äžã«ãããžã§ã³ãºã»ãããã³ã¹å€§åŠã®å®£äŒæ åœè ã¯ããæŠæŒ¢æµ·é®®åžå ŽãŠã€ã«ã¹ãææã«é¢é£ããçŸç ã«ããç±³åœã®æ»äº¡è ã¯çŽ100äžäººã§ãããšäŒããŠãããè±åœã®ã€ã³ããªã¢ã«ã»ã«ã¬ããžã®ããŒã«ã»ãã¡ãŒã¬ãœã³å士ãçããã¢ããªã³ã°ã»ããŒã ãšååããŠããããã®å®£äŒè ãã¡ã¯ãCOVID-19ã®èŽæ»çã¯3.4ïŒ ã§ãããšç¹°ãè¿ãäŒããŠããã
ãã®çäŸèŽæ»çã¯ãéåžžã«çç¥ãããè æãããç·æ¥äœ¿çšæ¿èªãèŠå¶ããã»ã¹ãçµãŠãããŸããŸãªè¬ããã¯ã¯ãã³ããè©°ã蟌ã¿ããããã®è£œåïŒå®å šã§ã广çã§ããªãããšã蚌æãããŠããïŒã鿥å»ãäžè¬åžæ°ã«æŒãä»ããããšãæ£åœåããããã«æŠåšåãããŠããããããã®å®éšç補åã¯ãäžå€®éæš©çãªãããããŠã³æ¹åŒã§ãæ€é²ãæŠäºå¿çãããã¬ã³ããäžæ£ãªééçã€ã³ã»ã³ãã£ãã鿥å»ã«ãã£ãŠéçºããå®å°è©Šéšãããããã ã¢ããã®æ²»çæ³ã®æå§ãç§åŠçã»å»åŠçæžå¿µãæèµ·ããè ãæ»æããå»çè¡çºãæå¹ãªç§åŠçè°è«ãžã®åå ã黿¢ããããã®ãå»çèªå¯ããã»ã¹ã®æšçåå«ããããšæŠåšåã®çµã¿åããã«ãã£ãŠæŒãä»ããããŠããã
ãã®ãããªäžå€®éæš©çãªæš©åšäž»çŸ©çæ¿çãšã¯å¯Ÿç §çã«ããã®ãããªãããããŠã³ã®æ¿çã®çŸ©ååãæåŠãããã®ãããªäžå€®éæš©çãªã°ããŒããªã¹ãã®ã墚ä»ãã®æ¿çã«åŸããªãã£ãããšã§ç¹°ãè¿ãå²ç¬ãããåœã§ããã¹ãŠã§ãŒãã³ã®ããŒã¿ã¯ãSARS-CoV-2ææè ã®èŽæ»çãçŽ0.026ããŒã»ã³ãã§ããããšã瀺ããŠããã2019幎ç§ã®ãããã³ã¹/CIA/ã²ã€ãã»ã¢ãžã§ã³ã201ããã³ãããã¯ãæŠäºã²ãŒã ã§ããã€ã³ããªã¢ã«ã»ã«ã¬ããžã®åã£ãã¢ããªã³ã°çµæã§ããå¶ç¶ã«ã3.4ããŒã»ã³ãã䜿ãããŠããããã§ã¯ãªããå®éã®ã¹ãŠã§ãŒãã³ã®ããŒã¿ãèæ ®ã«å ¥ããŠãçç·ŽããããŒã¿ã¢ããªã¹ãã¯COVIDç ã«ããå®éã®ç±³åœã®ç·æ»äº¡è æ°ã100äžäººã§ã¯ãªãã17äž1000人ãšèŠç©ãã£ãŠããã
æè¿ç·æ¥äœ¿çšãèš±å¯ããããããŒã¹ã¿ãŒã補åã«é¢ããæŽå²ãšçŸåšã®ããŒã¿ã«ã€ããŠå°ãèããŠã¿ããã
çŸåšãç·æ¥äºæ ã¯çºçããŠããªããCOVID-19ã«é¢é£ããçŸç ãšæ»äº¡ã®çºççã¯åºæ¬çã«ããŒã¹ã©ã€ã³ã«éããŠãããå»çç·æ¥äºæ 宣èšã¯2023幎5æã«æ£åŒã«è§£é€ãããã
ãããã®è£œåã¯ãFDAã®VRBACå§å¡äŒã®å©èšã«åºã¥ããŠèšèšããããã®ã§ãããåå§å¡äŒã¯æšå¹Žå€ãSARS-CoV-2æ ªã¯æ¬¡ã®ç§ã®ã·ãŒãºã³ãæ¯é ããæããã "ã¯ã©ãŒã±ã³ "æ ªã§ããããšäºæž¬ããŠããã
ãããã®è£œåãFDAã®èŠå¶èªå¯ãééããæºåãæŽãé ã«ã¯ããã¯ã©ãŒã±ã³ãå€ç°äœã¯ããšãªã¹ãå€ç°äœã«ãã£ãŠçµ¶æ» ããŠããããã®å€ç°äœã¯ææåã匷ããæäœã®ãäžåãã«å¯Ÿããæåæ§ãäœãããæåããšå®è³ªçã«åºå¥ã§ããªãèšåºçç¶ã䌎ããã®ã§ãã£ãããã¯ã©ãŒã±ã³ããšããšãªã¹ãã®ã¯ã¯ãã³æ ªäžäžèŽãšãããã©ããã¯ã¹ã«çŽé¢ããFDAãšCDCã¯ãå ç«ããŠã¹ã®è¡æž ãµã³ãã«ãšæ€èšŒãããŠããªããè¡æž äžå詊éšãã«äŸæ ããã¯ã©ãŒã±ã³ããŒã¹ã¿ãŒã¯ãšãªã¹å€çš®ãšååãªäº€å·®åå¿æ§ã瀺ãããã®è£œåã乳幌å ãå°å ãé幎ãæäººã«èªå¯ã販売ããããšãæ£åœåãããšäž»åŒµããïŒå®éã«ã¯å€éšã®å¯©æ»å®ãšããŒã¿ãåæãå ±æããããšãªãïŒã
ãããã®è£œåã®çºå£²ããããããªæéã§ãæ¿åºäž»å°ã®å®£äŒãã£ã³ããŒã³ã«ãããç±³åœã®æäººã§ã¯7ïŒ ãå°å ã§ã¯2ã3ïŒ ã®æåã確èªãããã
ãããŠä»ããã®æŒãããã "ã¯ã¯ãã³ "補åã®äžççãªæäžã«äŒŽãæ·æ±°å§ã®äžã§ãæ°ãã«HV.1ãšããåªå¢ãªäºçš®ã®é²åãèŠãããããã®å€çš®ã¯é説çã«ãé ãé¢ãããã«ã¿æ ªããã®ãšã¬ã¡ã³ãïŒãšãããŒãïŒãçµã¿èŸŒãã§ãããäžåæäœã«å¯ŸããŠéåžžã«æµææ§ããããHV.1ãçŸåšã®ããŒã¹ã¿ãŒã«ãã£ãŠèªçºãããæäœã«ãã£ãŠäžåãããããšã瀺ãããŒã¿ã¯ãªãã
ãã®æŽå²ã瀺ããŠããã®ã¯ãããšãFDAãäœå幎ã«ãããã£ãŠå¹ã£ãŠããå®å šæ§ãšæå¹æ§ã«é¢ããèŠç¯ãè¿åãããç·æ¥äœ¿çšèš±å¯ãã䜿ã£ãŠè£œåãèŠå¶åœå±ã®èªå¯ãééãããããšãåããªããšããŠããæ¹è¯åmRNAã¯ã¯ãã³ã®ãã©ãããã©ãŒã ã¯ãæ¥éã«é²åããRNAåŒåžåšãŠã€ã«ã¹ã«è¿œãã€ãããšãã§ããªããšããããšã§ããã
幎åããã®äººå·¥ãŠã€ã«ã¹ãããéå£ã«äŸµå ¥ããããšã«å¯Ÿããäžå€®éæš©çã§æš©åšäž»çŸ©çãªäžçç察å¿ã¯ãæããã«å€§å€±æã§ãã£ãã
ããã§ããã®æè¡ãšãã¯ã¯ãã³ã補åã®çŽåºŠã«é¢ããææ°æ å ±ãèããŠã¿ããã
ãã©ã€ã¢ã«ã»ãµã€ãã»ãã¥ãŒã¹ããããšããã¯ã»ã¿ã€ã ãºãçŽã®èšè ã«çŽé¢ãããšããFDAã¯è çç¶æ ã«é¥ã£ãã
FDAã¯ããæ®åDNAã®é åãéã«é¢é£ããå®å šæ§ã®æžå¿µã¯ç¢ºèªãããŠããªã ããšããäžçŽç©æ··å ¥ãå±éºæ§ãæåºãšããŠåŠå®ããã
FDAãèªå¯ãŸãã¯æ¿èªãããmRNA COVID-19ã¯ã¯ãã³ã®ãããããåžå Žããæé€ããããšãèŠæ±ããŠãããšãã䞻匵ã¯èª€ãã§ãããmRNAã¯ã¯ãã³ã¯10ååä»¥äžæäžãããŠãããæ®åDNAã®é åãéã«é¢ããå®å šæ§ã®æžå¿µã¯ç¢ºèªãããŠããŸãããFDAãæ¿èªããmRNAã¯ã¯ãã³ã«é¢ããŠã¯ãå ¥æå¯èœãªç§åŠç蚌æ ã«ãããå®å šãã€æå¹ã§ãããšããçµè«ãæ¯æãããŠããŸãã
å¯Ÿç §çã«ãModerna U.S. Patent #2019/0240317 A1ã¯ãModernaãã髿޻æ§éãŠã€ã«ã¹æ§è質ããç²åééã·ã¹ãã ã«ãã£ãŠæ£è ã«DNAãééããå ŽåãéºäŒåæ¯æ§ã®ãªã¹ã¯ãèªèããŠããããã®çµæããããéºäŒåã®æŽ»æ§åãŸãã¯ããæå¶éºäŒåã®é»å®³ã«ã€ãªããå¯èœæ§ã®ããæ¿å ¥çªç¶å€ç°èªçºã®å¯èœæ§ãå«ãåé¡ããçããããšãé瀺ããŠããã
ãã®äžå€®éæš©çãªãããããŠã³ã»ã¢ãããŒãïŒéèãæ¿åºãã°ããŒããªã¹ãçµç¹ã巚倧ãªéæ¿åºçµç¹ã®éé®ãã¡ã«ãã£ãŠæ¯æãããæšé²ãããŠããïŒã«é¢é£ããåé¯çã§ç¥éãªæ²åãšã¯å¯Ÿç §çã«ãæ¬æ¥ã¯ãéåžžã«ççæ§ã®é«ãåŒåžåšãŠã€ã«ã¹ã«ããçŸç ãšæ»äº¡ãé²ãããã«ãæ¢åã®è¬å±æ¹ãåå©çšããŠçç¶ã®æ²»çã«çŠç¹ãåœãŠããšããäŒçµ±çãªãããã ã¢ãããã¢ãããŒãããäžå€®éæš©çãªãããããŠã³ã»ã¢ãããŒããããã¯ããã«åªããŠããããšãå®èšŒãããå»åž«ãç§åŠè ã®ãã¬ãŒã³ããŒã·ã§ã³ãšèšŒèšããèãããã ããŸãã
ç§åŠçã»å»åŠççå®ãæš©åã«èšŽããåæ°ã®ãã人ã ã®ãããã§ãCOVID屿©ãšäžå€®éæš©çãªãããããŠã³ã»ã¢ãããŒãã®ãããã¬ã³ããè©æ¬ºã§ãã£ãããšãäžçã¯ãŸããŸãèªèãã€ã€ããã
ãã®è©æ¬ºãããŸããŸãªç®çã®ããã«æŠåšåããããšãã詊ã¿ã®äžã§ãç§ãã¡ã¯çãçŸä»£å²äžæãé©ãã¹ããäžå€®éæš©çã§ã°ããŒãã«åããããããã¬ã³ããšç²Ÿç¥æŠäºãã£ã³ããŒã³ã«ãããããŠããã
ä»åŸãç§ãã¡ã¯ãã¹ãã¢ãã³ã®è¶ çŸå®äž»çŸ©çãªæ å ±æ¯èгã®äžã«åºçŸããããã§ã¯çå®ã¯ãã¹ãã¢ãã³ã®é»éåŸã®å¯Ÿè±¡ãšãªããèš±ããããçå®ãã¯å®å šã«äž»èгçãªãã®ãšãªããæ¿åºãNGOãæ å ±æ©é¢ãäŒæ¥ã¡ãã£ã¢ã®å®æ°ããŒãããŒã·ããã«ãã£ãŠå®£äŒãããæªãã ç©èªãšãªã£ãŠãããã¢ããã³ããŒããã£ã³ããŒã³ã
ãããç§ãã¡ã®æµã ãå»çã®èªç±ãšå人ã®èªåŸã¯ç¢ºãã«éèŠã ããããããã以äžã«éèŠãªã®ã¯èªç±ãšå人ã®äž»æš©ã§ãããæ¿åºãåœæ°ã«è¿ä»£çãªç²Ÿç¥æŠäºèœåãè¡äœ¿ããããšãåããããŸãè¡äœ¿ã§ããããã«ãªãã°ãéžæã®å®å šæ§ã¯å®å šã«ç¡æå³ãªãã®ãšãªããç§ãã¡ã¯ã¿ãªãèªãã®éåœã远æ±ããåãäžããããç¬ç«ããå人ã§ã¯ãªããæ©èœçã«ãããããŒåããã幎å£å¥å ¬äººãšãªã£ãŠããŸãå±éºæ§ãããã
ã³ãŒãã©ãã£ãºã ã»ã°ããŒããªã¹ãã®å©çãä¿é²ããããã«å±éãããŠãããããããå šäœäž»çŸ©çãæš©åšäž»çŸ©çãªæ¿çã«æµæããè¬ãå»ãã¹ãæã¯éããŠããããããŠãå»çã®èªç±ã®æè·ã¯ããã®æå§ããšããŠããªãè¯ãå Žæã§ããã
çå®ã¯ã©ã€ãªã³ã®ãããªãã®ã§ãå®ãå¿ èŠã¯ãªããççã¯ã©ã€ãªã³ã®ãããªãã®ã§ãå®ãå¿ èŠã¯ãªãã